1352805-43-6Relevant articles and documents
HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS
-
Paragraph 000298, (2019/04/16)
Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis.
FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS
-
Page/Page column, (2013/03/26)
The present invention provides fused pyrrole derivatives of Formula I: wherein V, W, X, Y, L, Q, Ar, Z, R1 and R6 are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
